Co-Authors
This is a "connection" page, showing publications co-authored by Allison Naleway and Jennifer Kuntz.
Connection Strength
3.045
-
Knowledge About Respiratory Syncytial Virus and Acceptance of Infant Monoclonal Antibody for RSV and RSV Vaccination During Pregnancy. Pediatr Infect Dis J. 2025 Feb 01; 44(2S):S162-S166.
Score: 0.962
-
Development of an Intervention to Reduce Pain and Prevent Syncope Related to Adolescent Vaccination. Perm J. 2019; 23:17-136.
Score: 0.631
-
CASCADIA: a prospective community-based study protocol for assessing SARS-CoV-2 vaccine effectiveness in children and adults using a remote nasal swab collection and web-based survey design. BMJ Open. 2023 Jul 14; 13(7):e071446.
Score: 0.216
-
Incidence of SARS-CoV-2 infection among COVID-19 vaccinated and unvaccinated healthcare personnel, first responders, and other essential and frontline workers: Eight US locations, January-September 2021. Influenza Other Respir Viruses. 2022 Jan 13.
Score: 0.195
-
Feasibility of a pilot intervention to reduce pain and syncope during adolescent vaccination. Vaccine. 2018 06 22; 36(27):3937-3942.
Score: 0.151
-
Myocarditis and pericarditis are rare following live viral vaccinations in adults. Vaccine. 2018 03 14; 36(12):1524-1527.
Score: 0.148
-
Epidemiology of Symptomatic Human Metapneumovirus Infection in the CASCADIA Community-Based Cohort - Oregon and Washington, 2022-2024. MMWR Morb Mortal Wkly Rep. 2025 Apr 03; 74(11):188-193.
Score: 0.061
-
Household Transmission and Genomic Diversity of Respiratory Syncytial Virus (RSV) in the United States, 2022-2023. Clin Infect Dis. 2025 Mar 14.
Score: 0.061
-
Protection From COVID-19 Vaccination and Prior SARS-CoV-2 Infection Among Children Aged 6 Months-4 Years, United States, September 2022-April 2023. J Pediatric Infect Dis Soc. 2025 Jan 20; 14(1).
Score: 0.060
-
Effectiveness of mRNA COVID-19 vaccines and hybrid immunity in preventing SARS-CoV-2 infection and symptomatic COVID-19 among adults in the United States. J Infect Dis. 2025 Jan 08.
Score: 0.060
-
Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies. Environ Res. 2023 Oct 08; 239(Pt 1):117297.
Score: 0.055
-
Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers. Emerg Infect Dis. 2023 Mar; 29(3):599-604.
Score: 0.052
-
SARS-CoV-2 infection history and antibody response to three COVID-19 mRNA vaccine doses. Clin Infect Dis. 2022 Dec 29.
Score: 0.052
-
Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers. JAMA. 2022 10 18; 328(15):1523-1533.
Score: 0.051
-
Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort Study. JMIR Res Protoc. 2022 May 25.
Score: 0.050
-
Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. N Engl J Med. 2022 05 12; 386(19):1855-1857.
Score: 0.049
-
Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection. Clin Infect Dis. 2021 Dec 20.
Score: 0.048
-
Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER): Protocol for a Multisite Longitudinal Cohort Study. JMIR Res Protoc. 2021 Dec 03; 10(12):e31574.
Score: 0.048
-
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021 07 22; 385(4):320-329.
Score: 0.047
-
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 02; 70(13):495-500.
Score: 0.046